Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Total Liabilities (2021 - 2025)

Historic Total Liabilities for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $57.9 million.

  • Verrica Pharmaceuticals' Total Liabilities fell 1350.0% to $57.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.9 million, marking a year-over-year decrease of 1350.0%. This contributed to the annual value of $64.0 million for FY2024, which is 349.32% up from last year.
  • Per Verrica Pharmaceuticals' latest filing, its Total Liabilities stood at $57.9 million for Q3 2025, which was down 1350.0% from $56.6 million recorded in Q2 2025.
  • Verrica Pharmaceuticals' 5-year Total Liabilities high stood at $67.0 million for Q3 2024, and its period low was $3.8 million during Q1 2023.
  • For the 5-year period, Verrica Pharmaceuticals' Total Liabilities averaged around $45.0 million, with its median value being $47.9 million (2021).
  • As far as peak fluctuations go, Verrica Pharmaceuticals' Total Liabilities crashed by 9178.99% in 2023, and later soared by 160838.39% in 2024.
  • Quarter analysis of 5 years shows Verrica Pharmaceuticals' Total Liabilities stood at $47.5 million in 2021, then plummeted by 90.13% to $4.7 million in 2022, then skyrocketed by 1218.98% to $61.8 million in 2023, then grew by 3.49% to $64.0 million in 2024, then fell by 9.47% to $57.9 million in 2025.
  • Its Total Liabilities was $57.9 million in Q3 2025, compared to $56.6 million in Q2 2025 and $60.8 million in Q1 2025.